

# Comparing the clinical effectiveness, acceptability and cost-effectiveness of a 'stepping into day treatment' approach versus inpatient treatment as usual for anorexia nervosa

<b>Submission date</b> 17/02/2020	<b>Recruitment status</b> No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol
<b>Registration date</b> 28/02/2020	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 20/02/2024	<b>Condition category</b> Mental and Behavioural Disorders	<input type="checkbox"/> Individual participant data

## Plain English summary of protocol

### Background and study aims

Anorexia nervosa is a disabling and deadly disorder. About 20-30% of patients with anorexia nervosa need intensive treatment (day patient or inpatient treatment or both) to help them improve or recover. It is not known whether either of these two intensive treatment approaches has advantages/disadvantages for patients, families, the NHS and wider society. The aim of this study is to assess the effectiveness and acceptability of these two intensive treatment approaches: (a) specialist inpatient treatment as usual, and (b) specialist day patient treatment (either immediately or, if needed, after brief inpatient treatment to medically stabilise the patient), called 'stepped care', and to see whether they provide value for money.

### Who can participate?

People aged 17 and above with severe anorexia nervosa or a related disorder (e.g., avoidant /restrictive food intake disorder) and a body mass index (BMI) of 16kg/m<sup>2</sup> or below, who are in need of intensive treatment (e.g., due to illness severity, medical risk, or lack of response to outpatient psychological therapy)

### What does the study involve?

After providing informed consent, participants will complete questionnaires and a clinical interview to assess eating disorder symptoms, comorbid symptoms (e.g., mood), psychosocial adjustment, quality of life, and treatment motivation and expectations. Participants will then be randomly allocated to one of the two intensive treatment approaches: inpatient treatment-as-usual or the stepped care day-patient treatment approach. Participants' eating disorder symptoms will be monitored monthly from the first assessment to 12 months after random allocation. Participants will be asked to complete follow-up assessments (identical to the baseline assessment) at 6, 12 and 24 months after random allocation. If agreed by the patient, the researchers will also invite their main carer to complete two brief questionnaires at the start

of the study and 6, 12 and 24 months later. Following the 6-month assessment (updated 12/08 /2021, previously 12-month assessment), a sample of patients (20 per treatment group) and family carers (20 per treatment group) will be invited to complete a short audio-recorded qualitative interview with one of the researchers about their experiences of treatment within the study.

What are the possible benefits and risks of participating?

Both treatment approaches are effective, safe and routinely used in the NHS. The researchers expect participants to benefit in terms of improvement in eating disorder and related psychological and physical symptoms, quality of life, general well-being and relationships with close others. Additionally, many people enjoy being part of a large study such as this one, which helps answer important questions about the treatment and care given to patients in the NHS. Research assessment meetings with members of the research team (face-to-face or by phone) and the opportunity to think about their situation, progress and experiences of treatment often is also experienced as enriching by participants. This research will also enhance the evidence base on the treatment of people with severe anorexia nervosa. There may be some discomfort associated with completing questionnaires evaluating the outcome of treatment, although all the questionnaires given are very widely used and usually do not cause distress.

Where is the study run from?

King's College London and Specialist Eating Disorder Services across the UK

When is the study starting and how long is it expected to run for?

December 2019 to August 2022

Who is funding the study?

National Institute of Health Research (NIHR) Health Technology Assessment (HTA) Programme (UK)

Who is the main contact?

Başak İnce Çağlar, basak.ince@kcl.ac.uk

## Contact information

### Type(s)

Public

### Contact name

Dr Başak İnce Çağlar

### ORCID ID

<https://orcid.org/0000-0003-1177-3490>

### Contact details

Trial Coordinator  
PO59 Section of Eating Disorders  
Institute of Psychiatry, Psychology & Neuroscience  
King's College London  
De Crespigny Park  
London  
United Kingdom

SE5 8AF  
+44 (0)207 848 5608  
basak.ince@kcl.ac.uk

**Type(s)**  
Scientific

**Contact name**  
Prof Ulrike Schmidt

**ORCID ID**  
<https://orcid.org/0000-0003-1335-1937>

**Contact details**  
Principal Investigator  
PO59 Section of Eating Disorders  
Institute of Psychiatry, Psychology & Neuroscience  
King's College London  
De Crespigny Park  
London  
United Kingdom  
SE5 8AF  
-  
ulrike.schmidt@kcl.ac.uk

## **Additional identifiers**

**Integrated Research Application System (IRAS)**  
272903

**Central Portfolio Management System (CPMS)**  
43945

## **Study information**

### **Scientific Title**

A randomised controlled multi-centre open-label parallel-group non-inferiority trial of the clinical effectiveness, acceptability and cost-effectiveness of a 'stepping into day treatment' approach versus inpatient treatment as usual for anorexia nervosa in adult specialist eating disorder services

### **Acronym**

DAISIES

### **Study objectives**

This study aims to compare the clinical effectiveness, acceptability and cost-effectiveness of two intensive treatment approaches in routine NHS practice: specialist inpatient treatment as usual (IP-TAU) and a stepped care day treatment.

### **Ethics approval required**

Old ethics approval format

### **Ethics approval(s)**

Approved 14/04/2020, Wales Research Ethics Committee 5 (Health and Care Research Wales Castlebridge 4 15-19 Cowbridge Road East Cardiff, CF11 9AB, UK; +44 (0)7970 422139; Wales. REC5@wales.nhs.uk) ref: 20/WA/0072

### **Study design**

Randomized; Both; Design type: Treatment, Process of Care, Psychological & Behavioural, Complex Intervention, Qualitative

### **Primary study design**

Interventional

### **Study type(s)**

Treatment

### **Health condition(s) or problem(s) studied**

Anorexia nervosa

### **Interventions**

Current intervention as of 23/10/2020:

The researchers will start by assessing their ability to recruit participants (internal pilot trial; aiming to recruit 62 patients over 4 months). If this goes well, they will then progress to the full study, which will include 386 adults (including the pilot participants) with severe AN, who are deemed to need intensive treatment. Participants will be recruited from specialist eating disorder services across the UK. After completion of a baseline assessment, patients will be allocated by chance to either stepped care day treatment or IP-TAU.

#### **Inpatient treatment-as-usual (IP-TAU)**

IP-TAU uses the current standard patient care pathway. In this care pathway, patients admitted to a specialist eating disorder inpatient unit are treated until they reach a body mass index (BMI) of 18.5 kg/m<sup>2</sup> and normalise their eating, or get as close to this point as possible (e.g., a pre-defined BMI goal for patients with severe enduring AN). Patients admitted to IP-TAU are treated by a multidisciplinary team (including psychiatrists, psychologists, dieticians, nurses and others) and receive expert refeeding, therapeutic programmes and supervised meals and snacks. A proportion may also have day patient treatment at the end, at the discretion of the treating team.

#### **Stepped care day patient treatment approach**

This stepped care day patient treatment approach combines intensive day patient treatment with the option of inpatient treatment for medical stabilisation and progression to day patient treatment at the earliest opportunity. Regular risk assessments will be conducted with clear decision rules around patients' suitability for stepping down into multi-disciplinary specialist day patient treatment. Day patient treatment will involve 4-5 days a week with 2-3 meals per day, multi-disciplinary support (including psychiatrists, psychologists, dieticians, nurses and others) and high-quality evidence-based psychological interventions for patients and their carers. Patients will return home for weekends and evenings. Due to COVID-19, day patient treatment may be delivered using a blended approach of remote and physical attendance. Patients who are allocated to the stepped care intervention can either start day patient treatment immediately or be stepped down to day patient treatment after a period of inpatient treatment. The main aim

of the day patient treatment will be to treat patients until they reach a healthy weight and normalise their eating, or get as close to this point as possible.

The most important clinical outcome will be body mass index (BMI) at 12 months after randomisation. The researchers will test whether stepped care is no worse than inpatient treatment (a 'non-inferiority' study design). They will also assess a number of secondary outcomes, including eating disorder symptoms, comorbid symptoms, social functioning, quality of life, any relapses or re-admissions to hospital, as well as outcomes for carers. Additionally, they will evaluate treatment acceptability and participants' treatment experience (using both qualitative [interviews] and quantitative methods [questionnaires]). Finally, they will look at the cost of the two different treatment approaches and explore whether day patient treatment is better value for money than inpatient treatment to the NHS.

---

#### Previous intervention:

The researchers will start by assessing their ability to recruit participants (internal pilot trial; aiming to recruit 62 patients over 4 months). If this goes well, they will then progress to the full study, which will include 386 adults (including the pilot participants) with severe AN, who are deemed to need intensive treatment. Participants will be recruited from specialist eating disorder services across the UK. After completion of a baseline assessment, patients will be allocated by chance to either stepped care day treatment or IP-TAU.

#### Inpatient treatment-as-usual (IP-TAU)

IP-TAU uses the current standard patient care pathway. In this care pathway, patients admitted to a specialist eating disorder inpatient unit are treated until they reach a body mass index (BMI) of 18.5 kg/m<sup>2</sup> and normalise their eating, or get as close to this point as possible (e.g., a pre-defined BMI goal for patients with severe enduring AN). Patients admitted to IP-TAU are treated by a multidisciplinary team (including psychiatrists, psychologists, dieticians, nurses and others) and receive expert refeeding, therapeutic programmes and supervised meals and snacks. A proportion may also have day patient treatment at the end, at the discretion of the treating team.

#### Stepped care day patient treatment approach

This stepped care day patient treatment approach combines intensive day patient treatment with the option of inpatient treatment for medical stabilisation and progression to day patient treatment at the earliest opportunity. Regular risk assessments will be conducted with clear decision rules around patients' suitability for stepping down into multi-disciplinary specialist day patient treatment. Day patient treatment will involve 4-5 days a week with 2-3 meals per day, multi-disciplinary support (including psychiatrists, psychologists, dieticians, nurses and others) and high-quality evidence-based psychological interventions for patients and their carers. Patients will return home for weekends and evenings. Patients who are allocated to the stepped care intervention can either start day patient treatment immediately or be stepped down to day patient treatment after a period of inpatient treatment. The main aim of the day patient treatment will be to treat patients until they reach a healthy weight and normalise their eating, or get as close to this point as possible.

The most important clinical outcome will be body mass index (BMI) at 12 months after randomisation. The researchers will test whether stepped care is no worse than inpatient treatment (a 'non-inferiority' study design). They will also assess a number of secondary outcomes, including eating disorder symptoms, comorbid symptoms, social functioning, quality of life, any relapses or re-admissions to hospital, as well as outcomes for carers. Additionally,

they will evaluate treatment acceptability and participants' treatment experience (using both qualitative [interviews] and quantitative methods [questionnaires]). Finally, they will look at the cost of the two different treatment approaches and explore whether day patient treatment is better value for money than inpatient treatment to the NHS.

## **Intervention Type**

Mixed

## **Primary outcome(s)**

Body mass index (BMI) measured at 12 months post-randomisation

## **Key secondary outcome(s)**

Current secondary outcome measures as of 09/08/2021:

1. Body mass index (kg/m<sup>2</sup>) measured at baseline, 6- and 24-months post-randomisation and on a monthly basis from baseline to 12-months post-randomisation
2. Eating disorder symptomology measured using the Eating Disorder Examination (EDE) Interview at baseline, 6-, and 12-months post-randomisation, the Eating Disorder Examination Questionnaire – short form (EDE-QS) at baseline, 6-, and 12-months post-randomisation and on a monthly basis from baseline to 12-months post-randomisation, and the Eating Disorder Examination Questionnaire (EDE-Q) at 24-months post-randomisation
3. Comorbid symptomology measured using the Depression, Anxiety and Stress Scales – version 21 (DASS-21) and Obsessive Compulsive Inventory-Revised (OCI-R) at baseline and 6-, 12- and 24-months post-randomisation
4. Psychosocial adjustment measured using the Clinical Impairment Assessment (CIA), the Multidimensional Scale of Perceived Social Support (MSPSS), the Work and Social Adjustment Scale (WSAS) and the UCLA Loneliness Scale - Version 3 at baseline and 6-, 12- and 24-months post-randomisation
5. Treatment motivation measured using Motivational Rulers (willingness and readiness to change) at baseline and 6-, 12- and 24-months post-randomisation
6. Treatment acceptability measured using Visual Analogue Scales of treatment acceptability at baseline and 6-, 12- and 24-months post-randomisation
7. Cost and cost-effectiveness measured using the Health-related Quality of Life (EQ-5D-5L) at 6-, 12- and 24-months post-randomisation

Additional measures:

1. Autistic traits measured using the Autism Spectrum Quotient (AQ-10) at baseline
2. Treatment expectations measured using Visual Analogue Scales of treatment expectations at baseline
3. Service utilisation measured using the Adult Service Use Schedule (AD-SUS) modified for AN at baseline and 6-, 12- and 24-months post-randomisation and Hospital Episode Statistics (HES) will also be requested from NHS Digital (for participants from England) and Information Services Division (for participants from Scotland) to assess the number of hospital admission days (e.g., to A&E, specialist eating disorder units, and general psychiatric inpatient wards) in the year prior to participation in the study and 2-years post-randomisation
4. Treatment experience measured using the Therapeutic Environment Scale (TESS) at 3-months post-randomisation, and the Perceived Coercion Scale (PCS) at baseline and 6-months post-randomisation
5. COVID-19 diagnosis and symptoms measured using a purposely designed checklist at baseline and 6-, 12- and 24-months post-randomisation

6. Carer burden measured using the Depression, Anxiety and Stress Scales – version 21 (DASS21) and the Eating Disorders Symptom Impact Scale (EDSIS) at baseline and 6-, 12- and 24-months post-randomisation

---

Previous secondary outcome measures as of 23/10/2020:

1. Body mass index (kg/m<sup>2</sup>) measured at baseline, 6 and 24 months post-randomisation and on a monthly basis from baseline to 12 months post-randomisation
2. Eating disorder symptomology measured using the Eating Disorder Examination (EDE) Interview at baseline, 6, and 12 months post-randomisation, the Eating Disorder Examination Questionnaire – short form (EDE-QS) at baseline, 6, and 12 months post-randomisation and on a monthly basis from baseline to 12 months post-randomisation, and the Eating Disorder Examination Questionnaire (EDE-Q) at 24 months post-randomisation
3. Comorbid symptomology measured using the Depression, Anxiety and Stress Scales – version 21 (DASS-21) and Obsessive Compulsive Inventory-Revised (OCI-R) at baseline and 6, 12 and 24 months post-randomisation
4. Psychosocial adjustment measured using the Clinical Impairment Assessment (CIA), the Multidimensional Scale of Perceived Social Support (MSPSS), the Work and Social Adjustment Scale (WSAS) and the UCLA Loneliness Scale - Version 3 at baseline and 6, 12 and 24 months post-randomisation
5. Treatment motivation measured using Motivational Rulers (willingness and readiness to change) at baseline and 6, 12 and 24 months post-randomisation
6. Treatment experience measured using Visual Analogue Scales of treatment acceptability at baseline and 6, 12 and 24 months post-randomisation, the Therapeutic Environment Scale (TESS) at 3-months post-randomisation, the Perceived Coercion Scale (PCS) at baseline and 6 months post-randomisation, and the proportion of patients who self-discharge at 6 and 12 months post randomisation
7. Cost and cost-effectiveness measured using the Health-related Quality of Life (EQ-5D-5L) at baseline and 6, 12 and 24 months post-randomisation
8. Service utilisation measured using the Adult Service Use Schedule (AD-SUS) modified for AN at baseline and 6, 12 and 24 months post-randomisation and Hospital Episode Statistics (HES) will also be requested from NHS Digital (for participants from England) and Information Services Division (for participants from Scotland) to assess the number of hospital admission days (e.g., to A&E, specialist eating disorder units, and general psychiatric inpatient wards) in the year prior to participation in the study and 2 years post-randomisation
9. Carer burden measured using the Depression, Anxiety and Stress Scales – version 21 (DASS-21) and the Eating Disorders Symptom Impact Scale (EDSIS) at baseline and 6, 12 and 24 months post-randomisation

Moderators:

1. Autistic traits measured using the Autism Spectrum Quotient (AQ-10) at baseline
2. Treatment expectations measured using Visual Analogue Scales of treatment expectations at baseline
3. COVID-19 diagnosis and symptoms measured using a purposely designed checklist at baseline

Mediators:

1. COVID-19 diagnosis and symptoms measured using a purposely designed checklist at 6 and 12 months
-

Previous secondary outcome measures:

1. Body mass index (kg/m<sup>2</sup>) measured at baseline, 6 and 24 months post-randomisation and on a monthly basis from baseline to 12 months post-randomisation
2. Eating disorder symptomology measured using the Eating Disorder Examination (EDE) Interview at baseline, 6, 12, and 24 months post-randomisation and the Eating Disorder Examination Questionnaire – short form (EDE-QS) at baseline, 6, 12, and 24 months post-randomisation and on a monthly basis from baseline to 12 months post-randomisation
3. Comorbid symptomology measured using the Depression, Anxiety and Stress Scales – version 21 (DASS-21) and Obsessive Compulsive Inventory-Revised (OCI-R) at baseline and 6, 12 and 24 months post-randomisation
4. Psychosocial adjustment measured using the Clinical Impairment Assessment (CIA), the Significant Others Scale (SOS), the Work and Social Adjustment Scale (WSAS) and the Revised UCLA Loneliness Scale at baseline and 6, 12 and 24 months post-randomisation
5. Treatment motivation measured using Motivational Rulers (willingness and readiness to change) at baseline and 6, 12 and 24 months post-randomisation
6. Treatment expectations measured using Visual Analogue Scales at baseline
7. Treatment experience measured using Visual Analogue Scales of treatment acceptability at baseline and 6, 12 and 24 months post-randomisation, the Therapeutic Environment Scale (TESS) at 3-months post-randomisation, and the Perceived Coercion Scale (PCS) at baseline and 6 months post-randomisation
8. Cost and cost-effectiveness measured using the Health-related Quality of Life (EQ-5D-5L) and the Adult Service Use Schedule (AD-SUS) modified for AN at baseline and 6, 12 and 24 months post-randomisation
9. Hospital Episode Statistics (HES) will also be requested from NHS Digital (for participants from England) and Information Services Division (for participants from Scotland) to assess the number of hospital admission days (e.g., to A&E, specialist eating disorder units, and general psychiatric inpatient wards) in the year prior to participation in the study and 2 years post-randomisation
10. Carer burden measured using the Depression, Anxiety and Stress Scales – version 21 (DASS-21) and the Eating Disorders Symptom Impact Scale (EDSIS) at baseline and 6, 12 and 24 months post-randomisation

## Completion date

24/08/2022

## Eligibility

### Key inclusion criteria

Current inclusion criteria as of 04/09/2020:

1. Adults aged 17 years and above
2. Diagnostic and Statistical Manual of Mental Disorders (DSM)-5 diagnosis of severe anorexia nervosa (AN) or related disorder (e.g., avoidant/restrictive food intake disorder [ARFID; where food restriction and weight loss occur in the absence of concerns about shape and weight])
3. Body mass index (BMI) equal to or less than 16 kg/m<sup>2</sup>
4. In need for intensive treatment because of either rapid weight loss, and/or evidence of system /organ failure/medical instability and/or unsuccessful outpatient treatment
5. Have mental capacity to give informed consent to participate in the study

Previous inclusion criteria:

1. Male and female adults
2. Aged 17 years and above
3. Diagnostic and Statistical Manual of Mental Disorders (DSM)-5 diagnosis of severe anorexia

- nervosa (AN) or related disorder (e.g., avoidant/restrictive food intake disorder [ARFID; where food restriction and weight loss occur in the absence of concerns about shape and weight])
4. Body mass index (BMI) of less than 16 kg/m<sup>2</sup>
  5. In need for intensive treatment because of either rapid weight loss, and/or evidence of system /organ failure/medical instability and/or unsuccessful outpatient treatment
  6. Have mental capacity to give informed consent to participate in the study

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Adult

**Lower age limit**

17 years

**Sex**

All

**Total final enrolment**

15

**Key exclusion criteria**

Current exclusion criteria as of 04/09/2020:

1. Insufficient knowledge of English to complete study assessments or understand treatment
2. Severe learning disability
3. Severe medical or psychiatric (co)morbidity (e.g. psychosis, substance dependence) needing treatment in its own right
4. Those living too far away from day-patient treatment (and where no alternative arrangements for regular attendance at day-patient treatment can be made).

Previous exclusion criteria:

1. Insufficient knowledge of English to complete study assessments or understand treatment
2. Severe learning disability
3. Severe medical or psychiatric (co)morbidity (e.g. psychosis, substance dependence) needing treatment in its own right
4. Those living too far away from day-patient treatment (and where no alternative arrangements for regular attendance at day-patient treatment can be made).
5. Those who are involved in current research or have recently been involved in any research prior to recruitment

**Date of first enrolment**

16/11/2020

**Date of final enrolment**

25/03/2022

# Locations

## Countries of recruitment

United Kingdom

England

Scotland

## Study participating centre

### South London and Maudsley NHS Foundation Trust

Maudsley Hospital

Denmark Hill

London

United Kingdom

SE5 8AZ

## Study participating centre

### NHS Grampian

Summerfield House

2 Eday Road

Aberdeen

United Kingdom

AB15 6RE

## Study participating centre

### Central and North West London NHS Foundation Trust

Stephenson House

75 Hampstead Road

London

United Kingdom

NW1 2PL

## Study participating centre

### Leicestershire Partnership NHS Trust

Riverside House

Bridge Park Plaza

Bridge Park Road

Leicester

United Kingdom

LE4 8PQ

**Study participating centre**  
**Oxford Health NHS Foundation Trust**  
Warneford Hospital  
Warneford Lane  
Headington  
Oxford  
United Kingdom  
OX3 7JX

**Study participating centre**  
**South West London St George's Mental Health NHS Trust**  
Springfield Hospital  
61 Glenburnie Road  
London  
United Kingdom  
SW17 7DJ

**Study participating centre**  
**Surrey And Borders Partnership NHS Foundation Trust**  
18 Mole Business Park  
Randalls Road  
Leatherhead  
United Kingdom  
KT22 7AD

**Study participating centre**  
**NHS Dumfries and Galloway**  
Grierson House  
The Crichton  
Bankend Road  
Dumfries  
United Kingdom  
DG1 4ZG

**Study participating centre**  
**King's College London**  
P059 Psychological Medicine  
De Crespigny Park  
London  
United Kingdom  
SE5 8AF

**Study participating centre**  
**Dorset Healthcare University NHS Foundation Trust**  
Sentinel House  
4-6 Nuffield Road  
Nuffield Industrial Estate  
Poole  
United Kingdom  
BH17 0RB

**Study participating centre**  
**2gether NHS Foundation Trust**  
Rikenel  
Montpellier  
Gloucester  
United Kingdom  
GL1 1LY

**Study participating centre**  
**Birmingham and Solihull Mental Health NHS Foundation Trust**  
Unit 1, B1 50 Summerhill Road  
Ladywood  
Birmingham  
United Kingdom  
B1 3RB

## **Sponsor information**

**Organisation**  
King's College London

**ROR**  
<https://ror.org/0220mzb33>

## **Funder(s)**

**Funder type**  
Government

**Funder Name**

National Institute for Health Research

### Alternative Name(s)

National Institute for Health Research, NIHR Research, NIHRresearch, NIHR - National Institute for Health Research, NIHR (The National Institute for Health and Care Research), NIHR

### Funding Body Type

Government organisation

### Funding Body Subtype

National government

### Location

United Kingdom

## Results and Publications

### Individual participant data (IPD) sharing plan

Current IPD sharing statement as of 14/03/2023:

The datasets generated during and/or analysed during the current study will be available upon request from Prof. Ulrike Schmidt (Principal Investigator, [ulrike.schmidt@kcl.ac.uk](mailto:ulrike.schmidt@kcl.ac.uk)) or Dr Başak İnce Çağlar (Trial Coordinator, [basak.ince@kcl.ac.uk](mailto:basak.ince@kcl.ac.uk)).

Previous IPD sharing statement:

The datasets generated during and/or analysed during the current study will be available upon request from Prof. Ulrike Schmidt (Principal Investigator, [ulrike.schmidt@kcl.ac.uk](mailto:ulrike.schmidt@kcl.ac.uk)) or Dr Bethan Dalton (Trial Coordinator, [bethan.dalton@kcl.ac.uk](mailto:bethan.dalton@kcl.ac.uk)).

### IPD sharing plan summary

Available on request

### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>		23/03/2023	20/02/2024	Yes	No
<a href="#">Results article</a>		18/12/2023	20/02/2024	Yes	No
<a href="#">Protocol article</a>		16/06/2022	17/06/2022	Yes	No
<a href="#">HRA research summary</a>			28/06/2023	No	No